List view / Grid view
NICE has recommended Pfizer’s Xeljanz® (tofacitinib) as an option to…
NICE has recommended Pfizer’s Xeljanz® (tofacitinib) as an option to treat polyarticular juvenile arthritis and juvenile psoriatic arthritis.
The UK approval follows a Phase III study in which…
The UK approval follows a Phase III study in which Leqvio® (inclisiran) reduced low-density lipoprotein cholesterol (LDL-C) by 55 percent.
NICE has published draft guidance recommending Eli Lilly's twice-daily pill…
NICE has published draft guidance recommending Eli Lilly's twice-daily pill abemaciclib for advanced HER2-negative breast cancer.
A new approach to the cost-comparison fast-track appraisal process is…
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
NICE has recommended that Ultomiris (ravulizumab) be available on the…
NICE has recommended that Ultomiris (ravulizumab) be available on the NHS for patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome.
On the NICE’s recommendation, ravulizumab will be made available to…
On the NICE’s recommendation, ravulizumab will be made available to hundreds of patients with paroxysmal nocturnal haemoglobinuria on the UK’s NHS.
The recommendation will allow more data to be collected about…
The recommendation will allow more data to be collected about the combination treatment while allowing patients with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer to access the medication.
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately…
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately 2,000 NHS patients as a second line treatment for multiple myeloma.
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to…
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
Zolgensma, a one-off, potentially curative treatment for type 1 spinal…
Zolgensma, a one-off, potentially curative treatment for type 1 spinal muscular atrophy, is set to become the most expensive drug ever approved for use on the UK’s NHS.
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by…
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
NICE has recommended that the CAR T-cell therapy Tecartus be…
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
More than 1,000 people each year could benefit from treatment…
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
The regulatory body said that due to uncertainties surrounding the…
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia…
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
